Drug Utilization Review (DUR) Meeting Minutes
June 1, 2016

Members Present: Tanya Schmidt, Katie Kram, Wendy Brown, Peter Woodrow, Andrea Honeyman, Jeffrey Hostetter, Carlotta McCleary, Michael Booth, Gaylord Kavlie, Zach Marty

Members Absent: James Carlson, Michael Quast, Laura Schield, Russ Sobotta, Leneika Roehrich

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy

W. Brown called the meeting to order at 1:00 p.m. Chair W. Brown asked for a motion to approve the minutes of the March meeting. P. Woodrow moved that the minutes be approved, and M. Booth seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

DUR Board new members:
B. Joyce introduced Gaylord Kavlie and Zach Marty, the most recent members appointed to the DUR Board.

Budget update
B. Joyce gave the budget update. The pharmacy budget is currently projected to be $3-4 million under budget, largely due to drug rebates. In fourth quarter 2014, $10.2 million was paid out to pharmacies and $4.9 million was collected in rebates. In first quarter 2015, $11.2 million was paid out to pharmacies and $5.4 million was collected in rebates. In second quarter 2015, $11 million was paid out to pharmacies and $5.5 million was collected in rebates. In third quarter 2015, $7.9 million was paid out to pharmacies and $4.0 million was collected in rebates. In fourth quarter 2015, $10.4 million was paid out to pharmacies and $5.4 million was collected in rebates. In first quarter 2016, $10.6 million was paid out to pharmacies and $5.9 million was collected in rebates. In first quarter 2016 the first supplemental rebates were invoiced. To maximize the prior authorization and PDL programs, the department has added specific messages to the pharmacy claims system that will help pharmacies understand why a claim is rejecting.

Second reviews
A motion and second was made at the March meeting to place Glumetza, naloxone, naltrexone, Edecrin, interleukin-5 antagonist agents, acitretin, lice medications, NK_1 receptor antagonists, and Tirosint on prior authorization. The topics were brought up for a second review. Tommy Begres, representing Adapt Pharma, spoke regarding Narcan nasal spray. Contessa Fincher, representing Teva, spoke regarding Cinqair. Ted Sheedy, representing GSK, spoke regarding Nucala.
There was no public comment on Glumetza, Edecrin, IL-5 antagonist agents, acitretin, NK_1 receptor antagonists, and Tirosint. The motion to place Glumetza, Edecrin, IL-5 antagonist agents, acitretin, NK_1 receptor antagonists, and Tirosint on prior authorization passed with no audible dissent.

There were recommended wording changes on the naloxone rescue medications PA form. The first recommendation was to change “FDA approved indication” to “risk of opioid overdose due to opioid treatment or opioid use disorder.” The second recommendation was to change the wording regarding addiction counseling services to “has the patient been referred to addiction counseling services.” A motion was made by J. Hostetter to amend the naloxone form. K. Kram seconded. The amendments were passed and the form was approved with no audible dissent.

There were recommended wording changes on the naltrexone PA form. “Patient must have a diagnosis of” was changed to “FDA approved indication is.” A motion was made by K. Kram to

amend the naltrexone form. P. Woodrow seconded. The amendment was passed and the form was approved with no audible dissent.

There were recommended wording changes on the lice medications PA form. 'Patient must have failed a 30-day trial' was changed to 'patient must have failed a 28-day trial (2 applications)'. K. Kram made a motion to amend the lice medication form. Z. Marty seconded the motion. The amendment was passed and the form was approved with no audible dissent.

PDL
A. Murphy gave an update on the PDL. The most recent copy of the PDL was included for the Board to review.

Kits review
B. Joyce reviewed kits with the Board. Kits contain one product approved for use by the FDA and mandatory coverage mixed with or containing a non-FDA approved drug. Examples were included in the pack for the Board to review. There was no public comment. J. Hostetter made a motion to place kits on prior authorization. The motion was seconded by P. Woodrow. This topic will be reviewed at the next meeting.

DPP-4 inhibitors and combinations review
B. Joyce reviewed DPP-4 inhibitors and combinations with the Board. A motion was made by J. Hostetter to place DPP-4 inhibitors on prior authorization. The motion was seconded by K. Kram. There was no public comment. This topic will be reviewed at the next meeting.

Immune globulins review
A. Murphy reviewed immune globulins with the Board. A motion was made by K. Kram to place immune globulins on prior authorization. The motion was seconded by P Woodrow. There was no public comment. This topic will be reviewed at the next meeting.

Bowel prep agents review
B. Joyce reviewed bowel prep agents with the Board. A motion was made by K. Kram to place bowel prep agents on prior authorization. P. Woodrow seconded the motion. There was no public comment. This topic will be reviewed at the next meeting.

Topical antipsoriatics review
A. Murphy reviewed topical antipsoriatics with the Board. A motion was made by G. Kavlie to place topical antipsoriatics on prior authorization. P. Woodrow seconded the motion. This topic will be reviewed at the next meeting.

Platelet aggregation inhibitors review
A. Murphy reviewed platelet aggregation inhibitors with the Board. There was no public comment. M. Booth made a motion to place platelet aggregation inhibitors on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Antihyperuricemics review
B. Joyce reviewed antihyperuricemics with the Board. There was no public comment. J. Hostetter made a motion to place antihyperuricemics on prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Criteria recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. T. Schmidt moved to approve the new criteria, and J.

Hostetter seconded the motion. Chair W. Brown called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held September 7, 2016 in Bismarck. J. Hostetter made a motion to adjourn the meeting. P. Woodrow seconded. The motion passed with no audible dissent. W. Brown adjourned the meeting.

Closed session for profile review

Chair W. Brown called the closed session for profile review to order at 3:10. The board was updated on the recent RDUR letters that were mailed regarding over-utilization of short-acting beta-agonists. Other topics discussed included patients taking ADHD medications and narcotics concurrently and patients taking antipsychotics. After discussion, W. Brown adjourned the meeting at 3:40.